Anbenitamab Plus HB1801 Shows Promising Efficacy in HER2-Positive Advanced Breast Cancer: A Phase 3 Trial

Anbenitamab Plus HB1801 Shows Promising Efficacy in HER2-Positive Advanced Breast Cancer: A Phase 3 Trial

Highlight

This phase 3 study in China establishes the combination of anbenitamab, a HER2-targeted bispecific antibody, plus HB1801 (albumin-bound docetaxel) as a new promising regimen for HER2-positive advanced breast cancer, demonstrating a significant improvement in progression-free survival over the established THP (docetaxel, trastuzumab, pertuzumab) regimen.

Despite a higher incidence of grade 3 or higher adverse events with anbenitamab plus HB1801, the treatment shows a markedly higher objective response rate, suggesting enhanced anti-tumor activity.

Study Background

Human epidermal growth factor receptor 2 (HER2) positivity in advanced breast cancer defines a subset with aggressive disease requiring targeted therapy. The first-line standard combination therapy has involved docetaxel plus trastuzumab and pertuzumab (THP), which improves survival but leaves room for better therapeutic options. Bispecific antibodies like anbenitamab offer a novel mechanism, simultaneously targeting HER2 epitopes to potentially improve efficacy while adding chemotherapy agents such as albumin-bound docetaxel (HB1801) to optimize drug delivery and reduce toxicity.

Study Design

This was a multicenter, open-label, randomized phase 3 trial conducted in China enrolling 885 patients with HER2-positive advanced breast cancer. Patients were randomized 1:1 to receive either anbenitamab plus HB1801 or the standard THP regimen. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. Secondary endpoints included objective response rate (ORR) and safety profiles. The median follow-up for PFS assessment was 21 months.

Key Findings

At the predefined interim analysis with 401 PFS events, the 24-month progression-free survival rate was significantly higher with anbenitamab plus HB1801 versus THP (58.5% vs. 34.4%). The hazard ratio for progression or death was 0.46 (95% CI, 0.37 to 0.56; P<0.001), indicating a 54% reduction in the risk of progression or death. The objective response rate also favored the anbenitamab group (87.6% vs. 73.4%).

Regarding safety, grade 3 or higher adverse events were more frequent with anbenitamab plus HB1801 (45.9%) compared to THP (34.4%). Neutropenia was the most common grade ≥3 event in both groups (13.1% vs. 8.4%). Each group experienced 2 treatment-related deaths. These data reflect a manageable safety profile but highlight increased hematologic toxicity with the novel regimen.

Expert Commentary

The substantially improved PFS with anbenitamab plus HB1801 is clinically meaningful, particularly given the advanced stage of disease and increased ORR. Anbenitamab’s bispecific design may enhance HER2 blockade and immune engagement compared to trastuzumab and pertuzumab, though direct mechanistic studies are forthcoming. The higher toxicity rate, notably neutropenia, necessitates careful monitoring and management but does not currently overshadow the benefit.

Limitations include the open-label design and the exclusively Chinese patient population, which may affect generalizability. Further studies involving diverse populations and longer-term outcomes including overall survival and quality of life are warranted.

Conclusion

The combination of anbenitamab plus HB1801 represents a significant advancement in first-line treatment for HER2-positive advanced breast cancer, improving progression-free survival and objective response rates over the current THP regimen. While toxicity is increased, the benefit-risk balance appears favorable. These findings support consideration of this regimen as a new standard pending regulatory review and further confirmatory trials.

Funding and Trial Registration

This trial was funded by Shanghai JMT-Bio Technology and other collaborators. The study is registered on ClinicalTrials.gov under the identifier NCT05838066.

References

Wang J, Li H, Xu F, et al. Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2026 Oct 24; [Epub ahead of print]. PMID: 42929681.

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply